Imatinib Stada (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug stops the signalling pathways that promote cell division, survival and angiogenesis, leading to reduced tumour proliferation and increased cancer cell death.

The exact dose of Imatinib Stada is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, body weight, renal and hepatic function, and any concomitant therapies. Healthcare professionals follow approved dosing guidelines and may adjust the regimen according to therapeutic response and tolerability.

Safety data for Imatinib Stada in pregnancy and lactation are limited. The drug may pose risks to the developing fetus and to a nursing infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential benefits and risks with their treating physician before using the medication.

To request Imatinib Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard of care for several indications. Compared with newer agents, it has a well‑characterised safety profile and extensive clinical experience, though some newer inhibitors may offer activity against resistant mutations. Choice of therapy depends on disease characteristics, mutation status, prior treatment history and physician judgment.

Imatinib Stada should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and humidity, and do not store in the bathroom or near a kitchen sink.

Imatinib Stada is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow any specific instructions from their healthcare provider. The tablet should not be crushed or chewed unless the prescriber advises otherwise.

Serious risks include severe neutropenia or other cytopenias, hepatotoxicity with marked liver enzyme elevation, cardiac failure or reduced left‑ventricular function, pulmonary arterial hypertension, and life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored regularly for these events and report any concerning symptoms promptly.

Imatinib Stada is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised for individuals with severe cardiac disease, uncontrolled infections, or significant hepatic impairment. The drug should also be avoided in patients for whom the benefits do not outweigh the potential risks, as determined by a qualified clinician.